Drug discovery assays based on microcompetition for a limiting GABP complex
OwnerHanan Polanskyinventor
Life of this patent
Estimating the term…
Abstract
A recent discovery showed that microcompetition for GABP between a foreign polynucleotide and a cellular GABP regulated gene is a risk factor for some of the major chronic diseases, such as obesity, cancer, atherosclerosis, stroke, osteoarthritis, diabetes, asthma, and other autoimmune diseases. The invention uses this novel discovery to present assays for screening compounds based on their effectiveness in modulating such microcompetition, or the effects of such microcompetition on the cell. The selected compounds can be used in treatment of these chronic diseases. The invention also presents assays for screening compounds that can be used in treatment of chronic diseases resulting from other foreign polynucleotide-type disruptions.
Claims55
A method for evaluating the effectiveness of a compound for use in modulating the progression of a chronic disease, the method comprising the steps of:
- a. selecting a cell;
- b. introducing a polynucleotide foreign to said cell into said cell, or identifying a polynucleotide foreign to said cell in said cell;
- c. incubating said cell in the presence and absence of said compound;
- d. assaying microcompetition for GABP between said foreign polynucleotide and a polynucleotide natural to said cell;
- e. selecting a compound that can modify said microcompetition.
A method for evaluating the effectiveness of a compound for use in modulating the progression of a chronic disease, the method comprising the steps of:
- a. selecting a polynucleotide where said polynucleotide is natural to a certain first organism;
- and where said polynucleotide is empty in respect to said first organism;
- and where said polynucleotide is foreign to a second organism;
- b. introducing a polynucleotide foreign to said cell into said cell, or identifying a polynucleotide foreign to said cell in said cell;
- c. incubating said cell in the presence and absence of said compound;
- d. assaying microcompetition for GABP between said foreign polynucleotide and a polynucleotide natural to said cell;
- e. selecting a compound that can modify said microcompetition.
A method for evaluating the effectiveness of a compound for use in modulating the progression of a chronic disease, the method comprising of:
- 1) performing an assay capable of identifying compounds that perform a function selected from the group consisting of:
- a) modifying concentration of GABP;
- b) modifying phosphorylation of GABP;
- c) modifying affinity or avidity between members of the GABP family of proteins;
- d) modifying affinity or avidity between GABP and p300/cbp;
- e) modifying concentration of p300/cbp.
- 2) running sample compounds through said assay and selecting a compound that performs one of said functions.
A method for evaluating the effectiveness of a compound for use in modulating the progression of a chronic disease, the method comprising of:
- 1) performing an assay capable of identifying compounds that perform a function selected from the group consisting of:
- a) modifies expression of a GABP regulated gene;
- b) modifies activity of a gene product of a GABP regulated gene.
- 2) running sample compounds through said assay and selecting a compound that performs one of said functions.
A method for evaluating the effectiveness of a compound for use in modulating the progression of a chronic disease, the method comprising of:
- 1) performing an assay capable of identifying compounds that perform a function selected from the group consisting of:
- a) modifying concentration of a GABP kinase;
- b) modifying phosphorylation of a GABP kinase;
- c) modifying concentration of a GABP phosphatase;
- d) modifying phosphorylation of a GABP phosphatase;
- e) modifying affinity or avidity between GABP and a GABP kinase;
- f) modifying affinity or avidity between GABP and a GABP phosphatase;
- g) modifying oxidative effects on GABP.
- 2) running sample compounds through said assay and selecting a compound that performs one of said functions.
A method for monitoring the efficacy of a compound, or other treatments, in clinical trials for the treatment of a chronic disease in an animal or human subject, the method comprising assaying the effect of said compound on microcompetition for GABP between a polynucleotide natural to said subject and a polynucleotide foreign to said subject.
Dependencies are inferred from the claim text.